Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Shandong Provincial Hospital | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Tigecycline is a last-resort antibiotic that is used to treat severe infections caused by extensively drug-resistant bacteria. However, the efficacy and safety data for tigecycline in infectious patients are lacking. The aim of this study is to assess the efficacy and safety of tigecycline in infectious patients using pharmacokinetics and omics.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tigecycline | Drug | Efficacy and safety of Tigecycline |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events | Drug-related adverse events and serious adverse events | Through study completion, an average of 15 days |
| Pharmacokinetics of tigecycline | clearance in L/h | Through study completion, an average of 3 days |
| Rate constant for tigecycline distribution | Pharmacokinetics of tigecycline | Through study completion, an average of 3 days |
| The ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC). | PD target | Through study completion, an average of 3 days |
| Measure | Description | Time Frame |
|---|---|---|
| fibrinogen levels in mg/dL | Through study completion, an average of 3 days | |
| prothrombin time | prothrombin time in second | Through study completion, an average of 3 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients with severe infections
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wei Zhao, Ph.D | Contact | 86053188383308 | zhao4wei2@hotmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wei Zhao | Recruiting | Jinan | Shandong | China |
Not provided
| ID | Term |
|---|---|
| D003141 | Communicable Diseases |
| ID | Term |
|---|---|
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000078304 | Tigecycline |
| ID | Term |
|---|---|
| D013754 | Tetracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
Not provided
Not provided
Not provided
Not provided
Not provided
| activated partial thromboplastin time | activated partial thromboplastin time in second | Through study completion, an average of 3 days |
| international normalized ratio | international normalized ratio，INR | Through study completion, an average of 3 days |
| blood platelet count | blood platelet count in ×10^9/L | Through study completion, an average of 3 days |
| thrombin time | thrombin time in second | Through study completion, an average of 3 days |
| D006844 |
| Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |